tracking the news, one byte at a time
Freak Pulse
Category: Alzheimer’s Disease and Frontal Temporal Dementia
-
Roundup: New Models & AI, A human cell that tangles on its own, and more.
Research on Disease Mechanisms and New Models this week: A team at LMU Munich has engineered a human induced pluripotent stem cell (iPSC) model that endogenously expresses; and A research consortium centered at MIT has released…
-
Roundup: Dementia Research Challenges &, Blog Why Normal Cognition, and more.
Dementia Research Challenges & Community Insights this week: Preclinical Alzheimer’s trials targeting amyloid-positive but cognitively unimpaired individuals have repeatedly; and ENRICH Scotland’s Clinical Studies Officer details…
-
Roundup: Clinical Trial Results and Drug, Annovis Publishes Phase 2/3, and more.
Clinical Trial Results and Drug Development Updates this week: Annovis Bio has published Phase 2/3 results for buntanetap in mild-to-moderate Alzheimer’s disease in NPJ Dementia; and TauRx has published confirmatory study results in the…
-
Roundup: Blood Biomarkers for Dementia, p-tau217 goes commercial, and more.
Blood Tests & Biomarkers for Dementia Detection this week: A private healthcare provider, Echelon Health, is marketing a comprehensive dementia assessment that integrates the; and Rite Aid is offering p-tau217 blood testing as a…
-
Roundup: New Blood Tests and Biomarkers for, Spring 2026 Alzheimer’s Updates, and more.
New Blood Tests and Biomarkers for Early Detection this week: The Alzheimer’s disease clinical landscape is consolidating around biomarker-confirmed diagnosis and modestly; and In a 2026 update, Dr.
-
Roundup: Evaluating Alzheimer’s Drugs &, Alzheimers Drugs Provide No, and more.
Evaluating Alzheimer’s Drugs & Treatments this week: A 2026 Cochrane Review analysis of 17 clinical trials involving over 20,000 participants concludes that anti-amyloid; and This matters for Alzheimer’s Disease and Frontal Temporal…
-
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
Anavex Life Sciences presented new long-term data for its investigational oral therapy blarcamesine (Anavex 2-73) at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases.